FGEN FibroGen Inc.

FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast

Interested parties may access a live audio webcast of the conference call via the FibroGen website at . It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Dial-In Information

Live (U.S./Canada): (877) 658-9081

Live (International): (602) 563-8732

Confirmation number: 3055327

A replay of the webcast and investor presentation will be available shortly after the call for a period of 30 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 3055327.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For more information, please visit

Contacts:

FibroGen, Inc.

Investors:

Michael Tung, M.D.

Corporate Strategy / Investor Relations 

1.415.978.1434

 

Media:

Jennifer Harrington

+1.610.574.9196

 

 



EN
18/02/2021

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approxima...

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structurePhase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025Cash runway extended into 2028 SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today a...

September 2, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investme...

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available . FibroGen’s management team will b...

August 27, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca b...

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and del...

August 18, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Reports Second Quarter 2025 Financial Results and Provides Bu...

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant...

August 11, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat...

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burdenCompany intends to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive f...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch